Business Context and Reporting Period
This Form 10-Q covers Eli Lilly and Company for the quarter and nine months ended September 30, 1997. The company operates in pharmaceuticals, animal health, and health-care management (PCS Health Systems). A significant corporate event during the period was a two-for-one stock split effective September 24, 1997, with all per-share data adjusted accordingly.
Key Financial Metrics
| Metric | Q3 1997 | Q3 1996 | 9M 1997 | 9M 1996 |
|---|---|---|---|---|
| Net Sales ($ millions) | $2,160.1 | $1,803.9 | $6,101.8 | $5,285.5 |
| Gross Margin (%) | 72.8% | 72.1% | 72.5% | 71.1% |
| Net Income/Loss ($ millions) | $456.9 | $415.6 | $(842.6) | $1,150.5 |
| Earnings Per Share ($) | $0.41 | $0.38 | $(0.77) | $1.05 |
| Operating Cash Flow ($ millions) | N/A | N/A | $1,441.4 | $1,288.0 |
| Cash & Equivalents ($ millions) | $1,504.1 | N/A | $1,504.1 | $738.1 |
| Total Debt ($ millions) | $2,767.2 | N/A | $2,767.2 | $3,729.4 |
Note: Total debt is the sum of short-term borrowings ($423.4M) and long-term debt ($2,343.8M) as of Sept 30, 1997. Prior year debt figures are derived from the Dec 31, 1996 balance sheet ($1,212.9M short-term + $2,516.5M long-term).
Material Changes vs. Prior Period
- Revenue Growth: Q3 sales increased 20% year-over-year, driven by a 30% increase in U.S. sales and strong performance from new products (Gemzar, ReoPro, Zyprexa). Nine-month sales rose 15%.
- Asset Impairment: A non-cash charge of $2,443.0 million was recorded in the second quarter of 1997 related to the impairment of long-lived assets (primarily goodwill) in the PCS health-care-management business. This charge was the primary driver of the net loss for the nine-month period.
- Gain on Sale: The company recorded a gain of $631.8 million from the sale of its 40% interest in the DowElanco joint venture to The Dow Chemical Company.
- Product Performance: Prozac sales grew 11% in Q3 but faced international declines due to exchange rates and generic competition. Anti-infective sales declined 12% due to generic competition.
- Debt Reduction: Total debt decreased by approximately $962 million compared to the end of 1996, funded by operating cash flows and the DowElanco sale proceeds.
Guidance, Outlook, and Risks
- Outlook: Management expects gross margins for the full year to be higher than 1996 levels. R&D spending is projected to increase 14-16% for the year. Marketing and administrative expense growth is expected to approximate sales growth.
- Prozac Patents: Generic manufacturers (Barr and Geneva) have challenged the validity of Prozac patents. While the company believes the claims are without merit, an unfavorable outcome could materially affect financial results.
- Litigation: The company faces numerous product liability suits (Diethylstilbestrol, Prozac) and antitrust pricing lawsuits. Accruals for these liabilities are approximately $390 million, with estimated insurance recoverables of $240 million.
- Environmental: The company is a potentially responsible party for Superfund sites and has accrued for estimated cleanup costs.
Investor Verification Checklist
- Verify the sustainability of sales growth for new products (Gemzar, ReoPro, Zyprexa) versus the decline in anti-infectives.
- Monitor the status of patent litigation regarding Prozac and the potential impact of generic entry.
- Assess the future cash flow generation of the PCS health-care-management business post-impairment.
- Review the progress of antitrust and product liability settlements and the adequacy of insurance recoveries.
- Confirm the company's ability to maintain gross margin improvements amidst rising R&D and marketing costs.